Source study found

Story checked

Who really needs a heart calcium scan? | ScienceDaily (opens in a new tab)

sciencedaily.com · 2026-09-12

Short answerEvidenceSource

Short answer

Mostly supported

Mostly supported.

The claims we could check match the study, but some claims were not covered by the evidence reviewed.

3 supported
1 not covered

Checked against the study summary. The full text wasn't available, so some details couldn't be settled either way.

Share this check

Follow the evidence trail

The story

Who really needs a heart calcium scan? | ScienceDaily

sciencedaily.com · 2026-09-12

The story’s checkable claims.

Read the original story

NewsLink checks it

Mostly supported

Every claim we could check holds up. Three of four claims match the study. This overall rating is based only on the claims we could check. One claim the study doesn't address.

3 supported
1 not covered

Open claim evidence

The source study

Predictive Utility of Coronary Artery Calcium Score Added to the PREVENT Atherosclerotic Cardiovascular Disease Equations

JAMA · 2026

Open source record Open in Tessa

Then inspect each claim

Evidence layer

Claim by claim

Each claim gets a verdict. Expand it to see the evidence directly below.

Reading mode

Scan verdicts. Open evidence only when needed.

Browse by verdict

4 claims in this story

Showing all 4 claimsChoose a verdict to focus the list.

Claim 1 of 4Not coveredThe article says calcium scans may be unnecessary in low-risk people because of radiation exposure, testing, and costs, and may be unnecessary in high-risk people because statin treatment would already be recommended.View evidenceHide evidence

Why this verdict

The abstract-level profile supports selective CAC use mainly in borderline-to-intermediate risk groups, but it does not provide abstract evidence about radiation exposure, downstream testing, costs, or statin-treatment recommendations as reasons CAC may be unnecessary in low- or high-risk people. These may be discussed in the full article or clinical context, but they are not verifiable from the supplied abstract-depth paper profile.

Study evidence

Addition of CAC to PREVENT-ASCVD modestly increased discrimination for 10-year fatal and nonfatal ASCVD.Change in Harrell C = +0.02 (95% CI 0.01–0.03); baseline PREVENT Harrell C = 0.73 (95% CI 0.70–0.75).

“Longitudinal observational cohort study conducted at 6 sites in the United States and enrolling adult participants aged 45 to 79 years without ASCVD at baseline in the Multi-Ethnic Study of Atherosclerosis.”

Study evidence

In the PREVENT borderline-risk subgroup, observed 10-year incident ASCVD percentages were 1.9% (CAC=0), 3.9% (CAC >0 and <100), 7.4% (CAC 100–<300), and 14.3% (CAC ≥300).1.9%, 3.9%, 7.4%, 14.3% (10-year observed incident ASCVD by CAC category)

“Among those at borderline risk, incident ASCVD occurred in 1.9% of those with CAC score of 0, 3.9% with CAC greater than 0 and less than 100, 7.4% with CAC 100 or greater and less than 300, and 14.3% with CAC 300 or greater.”

Claim 2 of 4SupportedA 10-year study of more than 6,000 adults found that popular coronary calcium scans may add little to standard heart disease risk estimates for many people.View evidenceHide evidence

As statedlittle

Why this verdict

The abstract-level profile supports that this was a 10-year MESA cohort analysis of 6098 adults and that adding CAC to PREVENT produced only a small overall discrimination improvement: Harrell C increased by 0.02 from a PREVENT baseline of 0.73. The story’s hedged wording that scans “may add little” for many people is consistent with the paper profile.

Study evidence

“Longitudinal observational cohort study conducted at 6 sites in the United States and enrolling adult participants aged 45 to 79 years without ASCVD at baseline in the Multi-Ethnic Study of Atherosclerosis.”

Claim 3 of 4SupportedFor patients with borderline or intermediate risk, the scans could make a meaningful difference by revealing who is actually more likely to develop heart disease.View evidenceHide evidence

As statedmeaningful difference

Why this verdict

The paper profile reports that authors interpreted reclassification results as supporting selective CAC use in borderline-to-intermediate PREVENT risk groups. It also reports stepwise higher observed 10-year ASCVD incidence across CAC strata within the borderline-risk subgroup, from 1.9% with CAC=0 to 14.3% with CAC≥300. The story’s hedged statement that scans “could” make a meaningful difference by identifying higher-risk people is broadly supported at the abstract level, as long as it is understood as risk prediction/reclassification rather than proof that scanning improves outcomes.

Study evidence

“Longitudinal observational cohort study conducted at 6 sites in the United States and enrolling adult participants aged 45 to 79 years without ASCVD at baseline in the Multi-Ethnic Study of Atherosclerosis.”

Study evidence

“Among those at borderline risk, incident ASCVD occurred in 1.9% of those with CAC score of 0, 3.9% with CAC greater than 0 and less than 100, 7.4% with CAC 100 or greater and less than 300, and 14.3% with CAC 300 or greater.”

Claim 4 of 4SupportedThe overall study population showed only a small improvement when coronary artery calcium scoring was added to PREVENT, with discrimination rising from 0.73 to 0.75.View evidenceHide evidence

As stated0.73 to 0.75

Why this verdict

The profile directly supports the stated overall discrimination result: PREVENT base Harrell C was 0.73 and adding CAC increased the statistic by 0.02, corresponding to about 0.75. Characterizing this as a small improvement is consistent with the profile.

Study evidence

“Longitudinal observational cohort study conducted at 6 sites in the United States and enrolling adult participants aged 45 to 79 years without ASCVD at baseline in the Multi-Ethnic Study of Atherosclerosis.”

Then look for missing context

Context layer

What the story left out

Important study details the story did not include.

Categorical net reclassification improvement was modest but positive: NRI = 0.095 across prespecified PREVENT risk categories.
The story generally says scans may be useful for selected groups, but it does not report the NRI metric or its magnitude, which is one of the paper’s primary predictive-utility measures.
From Longitudinal observational cohort study (MESA)
Calibration results: calibration slopes were 1.09 for PREVENT base and 0.92 after adding CAC, with confidence intervals overlapping 1.0.
Calibration was one of the specified performance metrics in the paper profile, but the story presentation does not mention calibration or uncertainty around calibration change.
From Longitudinal observational cohort study (MESA)
The abstract profile does not substantiate radiation exposure, downstream testing, costs, or high-risk statin-treatment rationale as findings of this paper.
These clinical-practice considerations appear in the story presentation, but they are not present in the supplied abstract-depth paper profile. They therefore cannot be treated as reflected paper evidence at this depth.

5 things the story did carry across

Main study design and population: longitudinal observational MESA cohort of 6098 adults aged 45–79 without baseline ASCVD, followed for 10 years for fatal and nonfatal ASCVD events.
Overall predictive utility: adding CAC to PREVENT produced a small increase in discrimination, with Harrell C rising from 0.73 by +0.02, and modest overall reclassification.
Borderline-risk subgroup: observed 10-year ASCVD incidence rose across CAC categories, from 1.9% for CAC=0 to 14.3% for CAC≥300, supporting selective CAC use in borderline-to-intermediate PREVENT risk groups.
The evidence is observational and about prediction/reclassification, not a randomized test that CAC-guided management prevents ASCVD events.
Generalizability is limited to the MESA study population as reported: US adults aged 45–79 without baseline ASCVD.

Then read the study layer

Study layer

Study at a glance

Scan the study first. Expand only the parts you want to inspect.

Pieces of work

Evidence read

study summary

Lead result

human in vivo

1Lead resulthuman in vivoQuantify the change in predictive utility (discrimination, calibration, and reclassification) when adding coronary artery calcium (CAC) score to the PREVENT-ASCVD risk equations for 10-year ASCVD risk estimation in the MESA cohort.Longitudinal observational cohort study (MESA)Expand

In plain English

In the Multi-Ethnic Study of Atherosclerosis (MESA) cohort (n=6098 adults aged 45–79 years without baseline ASCVD), addition of coronary artery calcium (CAC) score to PREVENT-ASCVD 10-year risk equations produced a small improvement in discrimination (Harrell C increase 0.02, 95% CI 0.01–0.03) and modest categorical net reclassification improvement (NRI = 0.095, 95% CI 0.053–0.137) over 10 years of follow-up (366 ASCVD events). Calibration slopes were 1.09 (95% CI 0.93–1.25) for the PREVENT base model and 0.92 (95% CI 0.81–1.03) after adding CAC. Event rates among participants at borderline PREVENT risk varied by CAC strata (e.g., 1.9% for CAC=0; 14.3% for CAC≥300).

Key findings

Addition of CAC to PREVENT-ASCVD modestly increased discrimination for 10-year fatal and nonfatal ASCVD.Change in Harrell C = +0.02 (95% CI 0.01–0.03); baseline PREVENT Harrell C = 0.73 (95% CI 0.70–0.75).
Adding CAC produced a modest positive categorical net reclassification across specified PREVENT risk categories.Categorical NRI = 0.095 (95% CI 0.053–0.137).

“Longitudinal observational cohort study conducted at 6 sites in the United States and enrolling adult participants aged 45 to 79 years without ASCVD at baseline in the Multi-Ethnic Study of Atherosclerosis.”

2human in vivoDescribe risk reclassification and observed event rates within the guideline-relevant PREVENT risk strata (especially borderline/intermediate risk) by CAC categories to inform selective CAC use.cohort subgroup analysis / stratified incidence estimationExpand

In plain English

Within the PREVENT-defined borderline 10-year ASCVD risk group, observed 10-year incident ASCVD rates increased stepwise across CAC categories (CAC=0, >0–<100, 100–<300, ≥300). Authors state these reclassification results support selective use of CAC in borderline to intermediate PREVENT risk.

Key findings

In the PREVENT borderline-risk subgroup, observed 10-year incident ASCVD percentages were 1.9% (CAC=0), 3.9% (CAC >0 and <100), 7.4% (CAC 100–<300), and 14.3% (CAC ≥300).1.9%, 3.9%, 7.4%, 14.3% (10-year observed incident ASCVD by CAC category)
Authors interpret that these stratified incidence and reclassification results support selective use of CAC among those with borderline to intermediate PREVENT-estimated risk.

“Among those at borderline risk, incident ASCVD occurred in 1.9% of those with CAC score of 0, 3.9% with CAC greater than 0 and less than 100, 7.4% with CAC 100 or greater and less than 300, and 14.3% with CAC 300 or greater.”

What this piece can’t prove

Abstract presents descriptive subgroup incidence from an observational cohort; causal or management-effect inferences cannot be drawn from these data alone.
Generalizability limited to the MESA study population (US adults 45–79 y without baseline ASCVD) as reported.

1 further detail could not be confirmed from the summary.

Finally, the search trail

Method layer